Integrating Psychedelics into Mental Healthcare.

About

Awakn is integrating psychedelic medicine into mainstream mental healthcare to address a US$700bn annual problem in the UK and EU.  

We work across three divisions - Research, Clinics and Training. 

Our scientific team is led by Prof. David Nutt and Dr. Ben Sessa.


Market Potential

Annual mental health cost to the UK & EU economies US700bn

17%

of the population affected by mental health issues annually

3%

affected by alcohol and drug addiction

5%

affected by Anxiety

6%

affected by Eating Disorders

6%

affected by Depression

Divisions

We are integrating psychedelic medicine into mainstream mental healthcare across:

Research

Our extended team have led, and are leading, clinical trials that have defined the psychedelic medicine industry, including: The Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, Ketamine for reduction of Alcoholic Relapse (KARE), Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

 We specialise in clinical trials to help psychedelic drug development companies design clinical protocols for drug commercialisation and for not-for-profit entities interested in solving material public health issues.

Get in touch to learn more: 
research@awaknlifesciences.com 

Clinics

We will utilise the effects of the acute drug state induced by psychedelics alongside a course of psychotherapy to treat a range of mental health issues: Alcohol Addiction, Anxiety, Depression, and Eating Disorders.

Bristol Q1 2021   |   London & Manchester 2021   |  Birmingham & Brighton 2022

Get in touch to learn more: 
clinics@awaknlifesciences.com

Training

With both MDMA and Psilocybin predicted to be licensed and available for prescribing by doctors by 2022 the industry is going to require hundreds of clinicians who are trained and proficient at delivery psychedelic assisted psychotherapy over the next few years.

We provide accredited in person and online training.

Get in touch to learn more:
training@awaknlifesciences.com

Scientific Advisory Team

Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry.

002

Prof. David Nutt

Chairman, Scientific Advisory Board

Ben

Dr. Ben Sessa

Chief Medical Officer

celia

Prof. Celia Morgan

Advisor

michael

Dr. Michael Mithoefer

Advisor

ann

Ann Mithoefer, BSN

Advisor

001

Prof. Matthew Johnson 

Advisor

Corporate Team

0010

George Scorsis

Chairman

008

Anthony Tennyson

Chief Executive Officer

003

Jonathan Held

Chief Financial Officer

Ben

Dr. Ben Sessa

Chief Medical Officer

News

006-1

02.10.2020.

Proffessor Celia Morgan joins Awakn Life Sciences

007

24.09.2020.

Dr. Michael Mithoefer & Ann Mithoefer from MAPS Join Awakn's Scientific Board

005-1

08.09.2020.

Awakn Life Sciences Launches Clinical Research Division

003-1

02.09.2020.

Prof. Matthew Johnson Joins Awakn Life Sciences

004-1

24.09.2020.

Awakn Life Sciences Partners with Drug Science in the UK

002-1

07.07.2020.

Professor David Nutt Joins Awakn Life Sciences

ben2

18.06.2020.

Psychedelic Medical Start-Up Awakn Life Sciences Enters the UK Market with Dr. Ben Sessa

Videos

Current treatments produce sub-optimal patient outcomes, it's time for a different approach and different methods of treatment.

Dr. Ben Sessa: TEDx

Ben

Michael Pollan: Psychedelics solve mental health crisis

Michael_Pollan

Revealing the Mind: The Promise of Psychedelics

oo5

Professor David Nutt: TEDx

nutt

Contact

For all enquiries, complete the form and we’ll be in touch.

Locations

Clinic:
1 Regents Street, Bristol, BS8 4HW, United Kingdom

Main Office:
Suite 200, 366 Bay St, Toronto, Ontario, M5H 4B2, Canada

Awakn_logo_descriptor-02-1

© 2020 Awakn Life Sciences Inc